Associations between preoperative MR imaging metrics and WHO grade III per molecular subtypea
| Relative Comparison (Non-Reference:Reference)b | IDHmut-Codel | IDHmut-Noncodel | IDHwt |
|---|---|---|---|
| Tumor size (3rd to 1st quartile) | 0.97 (0.18–5.26) (P = .975) | 1.24 (0.34–4.57) (P = .742) | 1.60 (0.31–8.17) (P = .573) |
| Location (central:peripheral) | 1.55 (0.22–10.49) (P = .654) | 0.21 (0.05–0.80) (P = .035) | 0.42 (0.10–1.84) (P = .252) |
| No. of involved lobes (X + 1:X) | 1.45 (0.64–3.30) (P = .370) | 1.12 (0.65–1.94) (P = .673) | 0.96 (0.48–1.92) (P = .906) |
| Corpus callosum extension (yes:no) | 1.88 (0.39–9.05) (P = .430) | 2.51 (0.72–8.76) (P = .149) | 1.46 (0.25–8.35) (P = .672) |
| Hydrocephalus (yes:no) | 8.55 (0.33–223.32) (P = .197) | 2.07 (0.50–8.54) (P = .313) | 0.26 (0.01–5. 09) (P = .372) |
| Midline shift (3rd to 1st quartile) | 0.88 (0.37–2.10) (P = .774) | 0.55 (0.16–1.85) (P = .331) | 1.31 (0.91–1.89) (P = .148) |
| Eloquent cortex (yes:no) | 1.71 (0.49–5.99) (P = .402) | 1.87 (0.69–5.09) (P = .220) | 0.35 (0.08–1.54) (P = .165) |
| Ependymal extension (yes:no) | 1.68 (0.28–10.07) (P = .570) | 0.65 (0.15–2.86) (P = .571) | 0.09 (0.01–0.59) (P = .012) |
| Margins (global test)c | P = .970 | P = .360 | P = .221 |
| 33%–66%:<33%d | 1.20 (0.28–5.23) (P = .804) | 1.47 (0.37–5.79) (P = .583) | 1.62 (0.24–10.84) (P = .619) |
| >66%:<33%d | 1.16 (0.15–9.17) (P = .888) | 0.64 (0.12–3.56) (P = .614) | 0.27 (0.02–3.35) (P = .305) |
| >66%:33%–66%d | 0.96 (0.17–5.56) (P = .967) | 0.44 (0.13–1.42) (P = .170) | 0.16 (0.02–1.28) (P = .084) |
| Contrast enhancement (yes:no) | 1.73 (0.47–6.43) (P = .411) | 6.08 (2.12–17.41) (P = .001) | 16.75 (3.47–80.86) (P < .001) |
| Necrosis (yes:no) | 9.68 (0.83–112.49) (P = .070) | 0.61 (0.08–4.67) (P = .632) | 0.67 (0.13–3.36) (P = .630) |
↵a Note that for the multivariate logistic regression analysis, WHO grade III tumors were assigned the value 1 and WHO grade II tumors were assigned the value 0. Data are listed as adjusted odds ratios, (95% confidence interval) and corresponding P value determined by a Wald type III χ2 test.
↵b Relative comparison (nonreference:reference) identifies the nonreference predictor variable value/level and the reference predictor variable value/level at which the adjusted odds ratio was evaluated. For example (3rd:1st Quartile) represents a comparison of the adjusted odds for tumor grade III between 2 patients, 1 patient whose predictor variable value is at the 3rd quartile of the predictor variable empiric distribution (nonreference) and 1 patient whose predictor variable value is at the 1st quartile of the predictor variable empiric distribution (reference). A relative comparison denoted as (X + 1:1) represents a comparison of the adjusted odds for tumor grade III between 2 patients, 1 patient whose predictor variable value equals X + 1 (nonreference) and 1 patient whose predictor variable value equals X (reference). A relative comparison denoted as (yes:no) represents a comparison of the adjusted odds for a tumor grade III between 2 patients, 1 patient who has the factor of interest (nonreference = yes) and 1 patient who does not have the factor of interest (reference = no). Note, if the adjusted odds ratio is >1 (<1), it indicates that the estimate for the adjusted odds for a tumor grade III is greater (less) for the patient who has the nonreference predictor value/level.
↵c Global test P value is the P value for testing the null hypothesis that the adjusted odds ratio is same for all “margin” categories.
↵d Percentage of LGG displaying sharp/circumscribed margin.